Thank you, Mr. Chair.
I'll start with Mr. Davies' concluding remarks about the Patented Medicine Prices Review Board and the study.
We agreed that November 6 was the deadline for witnesses to submit plans to appear along with a brief or document that would help us make the right choices. However, I want to remind my colleagues that the committee voted on this type of motion because, throughout this whole process, people have been feeling denied the opportunity to come and speak. I wouldn't want us to interpret the limitation of witnesses in a narrow or exclusive way. I don't think that it's in our interest to do so. We must still see, on November 6, how many people have submitted a plan to appear along with a brief.
In terms of informal meetings, if there isn't any interpretation, then count me out. Clearly, we can work properly in a subcommittee as many times a week as we want. The bottom line is that I think that we should work formally, whether we do so in a committee or subcommittee. I'm not interested in informal meetings, especially if there isn't any interpretation. It must be made clear that this is out of the question.
It's time for us to start working. However, I supported this motion in particular to ensure that we don't overlook all the work done earlier. Logically speaking, when we want to be briefed on the topic, we usually need a summary. It turns out that the analysts have been working very hard. I wish that we could have received this and that we could have found a way to ask questions and have a short presentation. I think that, when we want to move forward, we must also look at what has been done and remember a number of things. I would have been in favour of this.
We're spending a considerable amount of time trying to find a methodology, but we're wasting a great deal of time right now. Maybe we should agree to speed up our approach a bit.
This was what I had to say this morning. I think that the constituents deserve to see us focus on this study, and we must move forward.